Phase I clinical trial of epitope peptides based vaccines targeting VEGFR1 in patients with advanced renal cell carcinoma

Phase I clinical trial of epitope peptides based vaccines targeting VEGFR1 in patients with advanced renal cell carcinoma - Phase I clincal trial of epitope peptides based vaccines targeting VEGFR1 in patients with advanced renal cell carcinoma

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004911

Enrollment

Registered

2011-01-20

Start date

2007-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced renal cell carcinoma

Interventions

Vaccination using epitope peptide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Performance status 0-2 HLA-A2 and/or -A24 No responce to (IL-2, IFN, sorafenib, sunitinib) etc

Exclusion criteria

Exclusion criteria: pregnancy uncontroled infection uncontroled cerebral metastasis etc

Design outcomes

Primary

Measure	Time frame
Safety	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026